A Three Way Sequential, Randomised, Open-Label Study Designed to Evaluate the Single and Multiple-Dose Pharmacokinetics and the Effect of Food on the Single-Dose Pharmacokinetics of Oral Sparsentan Suspension in Healthy Subjects
Latest Information Update: 05 Oct 2022
At a glance
- Drugs Sparsentan (Primary)
- Indications Focal segmental glomerulosclerosis; Hereditary nephritis; IgA nephropathy; Vasculitis
- Focus Pharmacokinetics
- Sponsors Travere Therapeutics
Most Recent Events
- 05 Oct 2022 New trial record